We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-3.93%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.2B
AUM Growth
-$117M
Cap. Flow
-$19.9M
Cap. Flow %
-1.66%
Top 10 Hldgs %
63.36%
Holding
73
New
12
Increased
16
Reduced
13
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$32M
2
NVO
Novo Nordisk
NVO
+$30.4M
3
IRTC icon
iRhythm Holdings
IRTC
+$18.8M
4
SNY icon
Sanofi
SNY
+$15M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$13.8M

Top Sells

Rank Stock Value
1
ZTS icon
Zoetis
ZTS
+$20.1M
2
UTHR icon
United Therapeutics
UTHR
+$18.9M
3
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$18.3M
4
GH icon
Guardant Health
GH
+$15.9M
5
AZN icon
AstraZeneca
AZN
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 92.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMTX icon
26
Immatics
IMTX
$1.24B
$11.3M 0.94%
1,294,103
+26,040
+2% +$206K
RXDX
27
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$10.9M 0.91%
+386,395
New +$11.2M
SRPT icon
28
Sarepta Therapeutics
SRPT
$1.66B
$9.84M 0.82%
131,245
+42,365
+48% +$3.12M
ZNTL icon
29
Zentalis Pharmaceuticals
ZNTL
$308M
$9.23M 0.77%
+328,397
New +$8.7M
HZNP
30
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$8M 0.67%
100,297
-132,597
-57% -$12.6M
SNDX icon
31
Syndax Pharmaceuticals
SNDX
$1.84B
$7.95M 0.66%
413,428
-303,636
-42% -$5.06M
OBSV
32
DELISTED
ObsEva SA Ordinary Shares
OBSV
$7.65M 0.64%
4,749,623
– –
ACET icon
33
Adicet Bio
ACET
$72.8M
$7.57M 0.63%
32,399
+6,381
+25% +$1.4M
AKUS
34
DELISTED
Akouos Inc
AKUS
$7.11M 0.59%
1,515,074
– –
ISEE
35
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$6.28M 0.52%
653,047
-368,164
-36% -$4.62M
CCXI
36
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$6.2M 0.52%
250,000
-50,000
-17% -$1.1M
ARGX icon
37
argenx
ARGX
$57.4B
$5.68M 0.47%
+15,000
New +$4.83M
BOLT icon
38
Bolt Biotherapeutics
BOLT
$7.36M
$5.62M 0.47%
137,722
– –
TVTX icon
39
Travere Therapeutics
TVTX
$5.33B
$5.15M 0.43%
212,593
-445,656
-68% -$11.2M
IMGN
40
DELISTED
Immunogen Inc
IMGN
$5.13M 0.43%
1,140,788
-287,381
-20% -$1.25M
SGEN
41
DELISTED
Seagen Inc. Common Stock
SGEN
$4.94M 0.41%
+27,894
New +$4.02M
KDNY
42
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.84M 0.4%
+276,609
New +$4.34M
XNCR icon
43
Xencor
XNCR
$1.44B
$4.33M 0.36%
158,164
-115,828
-42% -$2.86M
GERN icon
44
Geron
GERN
$911M
$4.33M 0.36%
2,791,630
+886,868
+47% +$1.25M
NCNA
45
NuCana
NCNA
$5.37M
$4.06M 0.34%
1,120
– –
GRTX
46
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$4.01M 0.33%
3,083,712
– –
AMLX icon
47
Amylyx Pharmaceuticals
AMLX
$2.05B
$3.61M 0.3%
187,381
+87,381
+87% +$1.04M
JNCE
48
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.98M 0.25%
981,928
-499,291
-34% -$2.43M
AGEN
49
Agenus
AGEN
$249M
$1.85M 0.15%
+48,542
New +$1.76M
INBX
50
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.68M 0.14%
147,935
-366,705
-71% -$5.39M
1
2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2022 Portfolio in Review

As of Q2 2022, Sofinnova Investments held 73 positions worth $1.2B, down 8.9% from $1.32B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sofinnova Investments's Q2 2022 filing shows 12 new, 16 increased, 13 reduced and 15 closed positions. Its largest new stake was Merck: 360,961 shares worth $32.9M. The largest sale was Zoetis, an estimated $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 89% a quarter earlier.

  • Sofinnova Investments's largest Q2 2022 buy was Merck: 360,961 shares worth $32.9M.
  • Sofinnova Investments added most to Karuna Therapeutics, Inc. Common Stock in Q2 2022, an estimated $13.8M increase.
  • Sofinnova Investments's biggest Q2 2022 reduction was United Therapeutics, cutting an estimated $18.9M.
  • Sofinnova Investments fully exited Zoetis in Q2 2022, selling an estimated $20.1M.
  • Sofinnova Investments's ten largest holdings make up 63% of its $1.2B portfolio in Q2 2022.
  • Sofinnova Investments opened 12 new positions and closed 15 in Q2 2022.
  • Sofinnova Investments's portfolio value fell 8.9% quarter-over-quarter to $1.2B.

Based on Sofinnova Investments's 13F filing for Q2 2022, filed 15 Aug 2022.